Benzyl benzoate is an aromatic benzenoid ester found naturally in balsamic and floral materials and is especially associated with Peru balsam and ylang-ylang type profiles. Compared with many archive constituents, it has relatively strong public literature for identity, topical scabicide use, and cosmetic safety review, but that evidence is largely pharmacologic or regulatory rather than aromatherapy-specific. The most defensible archive framing is that benzyl benzoate is a fragrance and balsam marker constituent with documented topical antiparasitic use and dose-dependent skin-irritation or sensitization considerations.
Chemical identity and composition
Benzyl benzoate has formula C14H12O2 and is the ester formed from benzyl alcohol and benzoic acid. Safety reviews group it with simple benzoates because its toxicology and disposition are interpreted alongside the broader benzyl alcohol and benzoic acid pathway family.
Aroma and practical use
- Use the recorded sweet, balsamic, faint, floral descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2024 randomized controlled trial reported a dermoscopy-verified cure rate of 87% with topical benzyl benzoate 25% vs 27% with permethrin 5% when both were used for three consecutive days.
The same abstract reported a burning sensation in 43% of benzyl benzoate users, which makes efficacy and tolerability both relevant to archive safety framing.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
The CIR safety assessment states there was no evidence of adverse pregnancy outcome in a study of topical benzyl benzoate 25% lotion in pregnant women.
That finding is exposure-specific and should not be generalized beyond topical therapeutic use, but it is one of the clearer human safety observations available for the isolated constituent.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
The same CIR review summarizes mixed or equivocal in vitro genotoxicity findings but negative in vivo genotoxicity assays for benzyl benzoate.
This supports cautious but not alarmist language: the safety profile is review-based and route-dependent rather than evidence-free.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard, Benzyl benzoate, CAS 120-51-4 (Amendment 49, 2020) - Category 4 (fine fragrance) maximum acceptable concentration in finished product 4.8%; restriction driven by dermal sensitization and systemic toxicity.Human use data support topical activity, but concentrated preparations can cause burning or irritation.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
Patch-test tables in the CIR review show occasional positive sensitization reactions, so archive wording should keep direct-contact claims conservative.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Older repeated-dose animal data in the CIR review include dermal toxicity signals at high exposure, including dermatitis and testicular atrophy in rabbits.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
topical neurotoxic action on mites
Recent scabies review snippets describe benzyl benzoate efficacy as linked to neurotoxic effects on mites rather than a host-mediated mechanism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
limited but measurable dermal penetration
CIR review text notes percutaneous absorption through human skin and urinary excretion after dermal exposure, supporting some systemic availability under concentrated topical use.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- This pass did not verify a strong isolated human inhalation or dermal aroma-use literature for benzyl benzoate outside pharmaceutical or cosmetic safety contexts.
- Natural-occurrence evidence is strong in archive oil records, but publicly accessible primary constituent-level occurrence papers were not all readable full-text during this pass.
- Mechanistic literature is dominated by antiparasitic use and safety review rather than broader constituent-specific functional biology.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.